Compare UCTT & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UCTT | BEAM |
|---|---|---|
| Founded | 1991 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 2004 | 2019 |
| Metric | UCTT | BEAM |
|---|---|---|
| Price | $45.07 | $24.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | ★ $132.83 | $52.15 |
| AVG Volume (30 Days) | 1.1M | ★ 1.5M |
| Earning Date | 10-27-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,734,500,000.00 | $24,000.00 |
| Revenue This Year | $32.43 | N/A |
| Revenue Next Year | $41.39 | $29.19 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $21.49 | $20.23 |
| 52 Week High | $144.22 | $38.26 |
| Indicator | UCTT | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 24.14 | 44.66 |
| Support Level | $41.87 | $22.65 |
| Resistance Level | $48.66 | $26.72 |
| Average True Range (ATR) | 3.52 | 1.20 |
| MACD | -1.98 | 0.07 |
| Stochastic Oscillator | 4.02 | 23.15 |
Ultra Clean Holdings Inc, through its subsidiaries, manufactures and supplies production tools, modules, and subsystems for the semiconductor capital equipment industry. The product includes precision robotic solutions, gas delivery systems, and a variety of industrial and automation production equipment products; subsystems include wafer cleaning subsystems, chemical delivery modules, top-plate assemblies, frame assemblies, and process modules. Its customer base includes firms in the semiconductor capital equipment industry, medical, energy, industrial, flat panel, and research equipment industries. It has two segments: Products and Services. Its principal markets are the Americas, Asia Pacific, and EMEA.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.